Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy

Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01276392

Enrollment

Registered

2011-01-13

Start date

2011-01-31

Completion date

2015-02-28

Last updated

2015-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Replacement Disorder

Keywords

regional and systemical anticoagulation, continuous renal replacement therapy, multiplate, rotational thrombelastometry

Brief summary

Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy

Exclusion criteria

* Age \< 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study

Design outcomes

Primary

Measure	Time frame	Description
Filter life time of continuous renal replacement therapy	Individual time point, standardized	Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.

Secondary

Measure	Time frame	Description
Activation of coagulation	beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis	blood samples for multiplate, rotem and systemic coagulation paramters

Countries

Germany

Outcome results